Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
NCT00393380 · The Emmes Company, LLC · PHASE2 · terminated · last registry update 2013-04-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study stopped because of toxicity concerns.” | – | Registry record, The Emmes Company, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-03-19Phase 3 first posted: Medical University of Vienna, Teriparatide + Placebo (NCT02091492)
- 2014-03-04Results posted on the registry: Columbia University, Risedronate + Teriparatide (NCT01611571)
- 2013-09-26Results posted on the registry: Massachusetts General Hospital, synthetic hPTH 1-34 (NCT00086619)
- 2013-07-11Phase 3 first posted: University Health Network, Toronto, Teriparatide 20 mcg (NCT01896011)
- 2013-07-11Results posted on the registry: Thomas J. Schnitzer, teriparatide (NCT00826228)
- 2013-04-24Results posted on the registry: University of Rochester, Teriparatide + Placebo (NCT00594906)
- 2013-02-28Phase 3 first posted: University of Zurich, osteoanabolic therapy (NCT01801397)
- 2013-02-21Phase 3 first posted: Amgen, Romozosumab + Teriparatide (NCT01796301)
- 2013-02-21Results posted on the registry: Unigene Laboratories Inc., PTH analog + Placebo (NCT01321723)
- 2013-01-16Also stopped (withdrawn): Leland Graves III, MD, teriparatide (NCT00347737)
- 2012-12-28Results posted on the registry: Eli Lilly and Company, Teriparatide + Aspara-CA 600 mg (NCT01430104)
- 2012-12-06Also stopped (terminated): M.D. Anderson Cancer Center, Teriparatide (Forteo) + Calcium (NCT00623974)
- 2012-10-23Results posted on the registry: Eli Lilly and Company, LY333334 + Placebo (NCT01250145)
- 2012-10-23Results posted on the registry: Eli Lilly and Company, Subcutaneous Teriparatide + Transdermal Teriparatide (NCT01011556)
- 2012-08-06Phase 3 first posted: Radius Health, Inc., Alendronate (NCT01657162)
- 2012-06-05Phase 3 first posted: Columbia University, Risedronate + Teriparatide (NCT01611571)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision